• Most Favored Nation Pricing Temporarily Halted By Courts

    In late December, the courts halted President Trump’s international reference-pricing scheme, the Most Favored Nation model, saying the administration had improperly attempted to implement a radical change in Medicare reimbursement policy.

  • Going Public In Mid-Pandemic

    Just as the COVID pandemic hit, Timber Pharma was planning on going public. But that wasn’t the only challenge the company faced in the months ahead.

  • 5 Elements Of A Long-Term Partnership Strategy

    Throughout my career, I have seen partnerships that succeed and those that fail. Through this experience, I have been able to identify what it takes to build and maintain partnerships that stand the test of time.

  • Benefits Of Beantown Biotech And Lessons For Life Science Leaders

    I have had the opportunity to experience and contribute to the thriving life sciences industry in Massachusetts, and I can say that it has all of the components needed to ultimately bring new treatments forward for patients.

  • Increasing Patient Diversity In Clinical Trials

    The COVID-19 pandemic has spotlighted healthcare’s biggest shortfalls. One of the most glaring problems sounds like it should be simple to resolve, but it has actually been challenging to implement — diversity in clinical trials.


  • Have You Heard Of The Chinese Biopharmaceutical Association (CBA)?

    While working at his first job at Human Genome Sciences in 1995, Guo-Liang Yu, Ph.D., decided to create The Chinese Biopharmaceutical Association (CBA), one of the largest Chinese American professional associations in the U.S.

  • What 4 Biopharma CFOs Think About The Future Of Remote Work

    While we touch on remote work in Life Science Leader’s annual outlook issue, the responses in this article from four biopharmaceutical CFOs to questions on the subject shed additional light on the challenge that lies ahead for employers.

  • Where Does Biopharma’s Future Reside Beyond Boston And San Francisco?

    Two metropolitan areas tend to dominate the discussion when it comes to key biopharmaceutical industry hubs within the United States — Boston and San Francisco. And while these two cities have certainly earned their biopharma bragging rights over the years, one has to wonder how long that will continue. Afterall, just a few years ago biopharmaceutical executives noted it becoming increasingly difficult to attract top talent, as candidates cited “too crowded,” “too expensive,” and a host of other reasons behind their unwillingness to move to places like Boston and San Francisco. But does location (for many roles) even still apply?